Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

[C-reactive protein changes with antihypertensive and statin treatment].

Rodilla E, Gómez-Belda A, Costa JA, Aragó M, Miralles A, González C, Pascual JM.

Med Clin (Barc). 2005 Oct 29;125(15):561-4. Spanish.

PMID:
16277947
2.
3.

Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy.

Yan X, Li Y, Dong Y, Wu Y, Li J, Bian R, Hu D.

Lipids Health Dis. 2019 Jan 29;18(1):32. doi: 10.1186/s12944-019-0974-y.

4.

Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy.

Rabkin SW, Langer A, Ur E, Calciu CD, Leiter LA.

Hypertens Res. 2013 Jun;36(6):550-8. doi: 10.1038/hr.2012.214. Epub 2013 Feb 7.

PMID:
23388885
5.

Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.

Kanbay M, Yildirir A, Bozbas H, Ulus T, Bilgi M, Muderrisoglu H, Akcay A, Ozdemir FN.

Ren Fail. 2005;27(3):297-303.

PMID:
15957546
6.

Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists.

Yoshika M, Komiyama Y, Masuda M, Yokoi T, Masaki H, Ohkura H, Takahashi H.

Clin Exp Hypertens. 2010;32(6):341-6. doi: 10.3109/10641961003628460.

PMID:
21028996
7.

Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.

Rizos CV, Milionis HJ, Kostapanos MS, Florentin M, Kostara CE, Elisaf MS, Liberopoulos EN.

Clin Ther. 2010 Mar;32(3):492-505. doi: 10.1016/j.clinthera.2010.03.018.

PMID:
20399986
9.

Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia.

Pareek A, Chandurkar N, Thulaseedharan NK, Legha R, Agarwal M, Mathur SL, Salkar HR, Pednekar S, Pai V, Sriram U, Khyalappa R, Parmar M, Agrawal N, Dhruv U, Saxena S.

Curr Med Res Opin. 2015 Nov;31(11):2105-17. doi: 10.1185/03007995.2015.1087989. Epub 2015 Oct 8.

PMID:
26371518
10.

Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.

Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y.

Heart Vessels. 2008 Mar;23(2):91-5. doi: 10.1007/s00380-007-1008-7. Epub 2008 Apr 4.

PMID:
18389332
11.

Statin therapy may prevent restenosis after successful coronary intervention, independent of lipid-lowering effect and CRP level.

Yamawaki T, Yamada A, Fukumoto Y, Kishi T, Sobashima A, Kuwata K, Nakamura R, Sekiya M, Ando H, Okamatsu S.

Fukuoka Igaku Zasshi. 2007 Jun;98(6):260-9.

PMID:
17665547
12.

Long-term effects of statins on arterial pressure and stiffness of hypertensives.

Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, Saruta T.

J Hum Hypertens. 2005 Feb;19(2):103-9.

PMID:
15361892
13.

Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia.

Sirenko Y, Radchenko G; PERSPECTIVA Study Group.

High Blood Press Cardiovasc Prev. 2017 Mar;24(1):85-93. doi: 10.1007/s40292-017-0184-5. Epub 2017 Feb 2.

PMID:
28150140
14.

On-treatment C-reactive protein and HDL cholesterol levels in patients at intermediate cardiovascular risk: impact on carotid intima-media thickness.

Pirro M, Vaudo G, Lupattelli G, Pasqualini L, Mannarino MR, Schillaci G, Alaeddin A, Paciullo F, Fallarino F, Bagaglia F, Mannarino E.

Life Sci. 2013 Sep 3;93(8):338-43. doi: 10.1016/j.lfs.2013.07.008. Epub 2013 Jul 19.

PMID:
23871987
15.

Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).

Erdine S, Ro YM, Tse HF, Howes LG, Aguilar-Salinas CA, Chaves H, Guindy R, Chopra P, Moller RA, Schou IM; Gemini-AALA Investigators.

J Hum Hypertens. 2009 Mar;23(3):196-210. doi: 10.1038/jhh.2008.114. Epub 2008 Sep 18.

PMID:
18800143
16.

Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease.

Poussa H, Strandberg TE, Tikkanen I, Kauhanen P, Lepäntalo M.

Scand Cardiovasc J. 2007 Jun;41(3):138-41.

PMID:
17487761
17.

Optimal Medical Management Reduces Risk of Disease Progression and Ischemic Events in Asymptomatic Carotid Stenosis Patients: A Long-Term Follow-Up Study.

Shah Z, Masoomi R, Thapa R, Wani M, Chen J, Dawn B, Rymer M, Gupta K.

Cerebrovasc Dis. 2017;44(3-4):150-159. doi: 10.1159/000477501. Epub 2017 Jul 8.

PMID:
28689200
18.

Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.

Straczek C, Tafflet M, Barberger-Gateau P, Bertrand M, Dupuy AM, Ducimetière P, Empana JP.

Atherosclerosis. 2011 Feb;214(2):426-31. doi: 10.1016/j.atherosclerosis.2010.10.040. Epub 2010 Nov 3.

PMID:
21129746
19.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
20.

Blood pressure and lipid target adherence in Korean patients receiving angiotensin II receptor blockers/statin regimens.

Kim HJ, Kim E, Min KB, Min JY.

Curr Med Res Opin. 2017 Feb;33(2):385-390. doi: 10.1080/03007995.2016.1257982. Epub 2016 Dec 2.

PMID:
27819152

Supplemental Content

Support Center